Ionis Pharmaceuticals, Inc. (IONS) is a Biotechnology company in the Healthcare sector, currently trading at $76.76. It has a SharesGrow Score of 46/100, indicating a mixed investment profile with 3 out of 7 criteria passed.
Analyst consensus target is IONS = $96 (+25.6% upside).
Valuation: IONS trades at a trailing Price-to-Earnings (P/E) of -32.1 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.45.
Financials: revenue is $944M, +19.2%/yr average growth. Net income is $381M (loss), growing at -14.5%/yr. Net profit margin is -40.4% (negative). Gross margin is 98.3% (+0.7 pp trend).
Balance sheet: total debt is $2.6B against $489M equity (Debt-to-Equity (D/E) ratio 5.35, leveraged). Current ratio is 3.83 (strong liquidity). Debt-to-assets is 74.2%. Total assets: $3.5B.
Analyst outlook: 20 / 32 analysts rate IONS as buy (63%) — moderate consensus.
SharesGrow 7-Criteria breakdown: Value 92/100 (Pass), Growth 48/100 (Partial), Past 0/100 (Fail), Health 33/100 (Fail), Moat 72/100 (Pass), Future 67/100 (Pass), Income 10/100 (Fail).
